Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

Pancreatic cancer is one of the deadliest types of cancer, with fewer than 13% of people diagnosed with it surviving for more ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Clinical studies suggest that the mRNA vaccine may play a role in treating pancreatic cancer, identified as one of the most ...

Recent positive lab confirmation of Smart mRNA functionality is a tremendous milestone for the Company. This marks a ...

The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with ...

A new type of mRNA vaccine, added to standard cancer treatment, could help some patients with pancreatic cancer live longer.

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...

Several ASX-listed healthcare companies with low market caps are making strides in tackling cancer,  a leading cause of death ...

As few as one in ten people survive pancreatic cancer five years after their diagnosis — making it the most difficult cancer to survive. The survival rate five years after diagnosis is 6-14%, but ...